Effect of Previous-Year Vaccination on the Efficacy, Immunogenicity, and Safety of High-Dose Inactivated Influenza Vaccine in Older Adults

April 10, 2016 at 12:55 pm

Clinical Infectious Diseases May 1, 2016 V.62 N.9 P.1092-1099

Carlos A. DiazGranados, Andrew J. Dunning, Corwin A. Robertson, H. Keipp Talbot, Victoria Landolfi, and David P. Greenberg

1Sanofi Pasteur, Swiftwater, Pennsylvania

2Vanderbilt University Medical Center, Nashville, Tennessee

3Department of Pediatrics, University of Pittsburgh School of Medicine, Pennsylvania


High-dose inactivated influenza vaccine (IIV-HD) is an alternative to the standard-dose inactivated influenza vaccine (IIV-SD) in the United States for influenza prevention in older adults. IIV-HD improved efficacy relative to IIV-SD in a randomized controlled trial. Recent observational studies suggest that previous influenza vaccination may influence the immunogenicity and effectiveness of current-season vaccination.


The original study was a double-blind, randomized trial comparing IIV-HD to IIV-SD in adults aged ≥65 years over 2 influenza seasons. A subset of year 1 (Y1) participants reenrolled in year 2 (Y2), receiving vaccine by random assignment in both years. We evaluated the effect of Y1 vaccination on Y2 relative vaccine efficacy (VE), immunogenicity (hemagglutination inhibition [HAI] titers), and safety among reenrolled participants.


Of 14 500 Y1 participants, 7643 reenrolled in Y2. Relative to participants who received IIV-SD both seasons, VE was higher for IIV-HD vaccinees in Y2 (28.3% overall; 25.1% for Y1 IIV-HD, Y2 IIV-HD; and 31.6% for Y1 IIV-SD, Y2 IIV-HD). In multivariate logistic regression models, Y1 vaccine was not a significant modifier of Y2 VE (P = .43), whereas Y2 IIV-HD remained significantly associated with lower influenza risk (P = .043). Compared to administration of IIV-SD in both years, postvaccination HAI titers were significantly higher for patterns that included IIV-HD in Y2. No safety concerns were raised with IIV-HD revaccination.


IIV-HD is likely to provide clinical benefit over IIV-SD irrespective of previous-season vaccination with IIV-HD or IIV-SD. IIV-HD consistently improved immune responses, and no safety concerns emerged in the context of IIV-HD revaccination.





Entry filed under: Infecciones respiratorias, Infecciones virales, Influenza, Inmunizaciones, Update.

Diagnóstico y el tratamiento de la bacteriemia y endocarditis por Staphylococcus aureus. Una guía de práctica clínica de la Sociedad Española de Microbiología Clínica y Enfermedades Infecciosas (SEIMC) Protective Effect of Contemporary Pertussis Vaccines: A Systematic Review and Meta-analysis


April 2016
« Mar   May »

Most Recent Posts

%d bloggers like this: